Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Background: Inotuzumab ozogamicin (InO) is a humanized antibody-drug conjugate that targets CD22+ B-cells. InO demonstrated antitumor activity and manageable toxicity in phase 1/2 trials for the treatment of B-cell non-Hodgkin lymphoma (NHL) as a single agent and in combination with rituximab. In or...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.233-233
Hauptverfasser:	Khouri, Issa F., Alzahrani, Kamal, Gulbis, Alison, Sasaki, Koji, Jain, Nitin, Short, Nicholas J., Kadia, Tapan M., Daher, MD, May, Rafei, Hind, Im, Jin S, Marin, David, Olson, Amanda L., Popat, Uday R., Qazilbash, Muzaffar H., Ramdial, Jeremy, Rondon, Gabriela, Srour, Samer A., Kebriaei, Partow, Shpall, Elizabeth J., Kantarjian, Hagop M., Champlin, Richard E., Jabbour, Elias
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!